Development and validation of bioanalytical methods for Imidafenacin (KRP-197/ONO-8025) and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 853, Issue 1-2, 2007, Pages 70-79

  Masuda, Yuichi ^a   Kanayama, Norihiro ^a   Manita, Shigeru ^a   Ohmori, Satoshi ^a   Ooie, Tsuyoshi ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Human plasma; Imidafenacin; KRP 197; LC MS MS; Metabolites; ONO 8025

Indexed keywords

BLADDER; IMIDAFENACIN; KRP-197; ONO-8025;

BIOLOGICAL ORGANS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIZATION POTENTIAL; MASS SPECTROMETRY; METABOLITES; PLASMA (HUMAN);

DRUG PRODUCTS;

DRUG METABOLITE; IMIDAFENACIN; IMIDAZOLE DERIVATIVE; KRP 197; MUSCARINIC RECEPTOR BLOCKING AGENT; ONO 8025; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ARTICLE; ATMOSPHERIC PRESSURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MASS SPECTROMETRY; NORMAL HUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REACTION ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; VALIDATION PROCESS;

CHROMATOGRAPHY, LIQUID; HUMANS; IMIDAZOLES; MOLECULAR STRUCTURE; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 34250019717     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2007.02.047     Document Type: Article

References (13)

1. Andersson K.E., and Yoshida M. Eur. Urology 43 (2003) 1
2. Chapple C.R., Yamanishi T., and Chess-Williams R. Urology 60 Suppl. 5A (2002) 82
3. Robinson D., and Cardozo L. Int. J. Clin. Pract. 59 (2005) 1229
4. Kobayashi F., Yageta Y., Segawa M., and Matsuzawa S. Arzneim. Forsch. /Drug Res. 57 (2007) 92
5. Miyachi H., Kiyota H., and Segawa M. Bio. Med. Chem. Lett. 9 (1999) 3003
6. Miyachi H., Kiyota H., Uchiki H., and Segawa M. Bio. Med. Chem. 7 (1999) 1151
7. Matsui M., Motomura D., Karasawa H., Fujikawa T., Jiang J., Komiya Y., Takahashi S., and Taketo M.M. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 9579
8. Nelson C.P., Gupta P., Napier C.M., Nahorski S.R., and Challiss R.A. J. Pharmacol. Exp. Ther. 310 (2004) 1255
9. Somogyi G.T., de Groat W.C., and Auton J. Nerv. Syst. 37 (1992) 89
10. Braverman A.S., Kohn I.J., Luthin G.R., and Ruggieri M.R. Am. J. Physiol. 274 (1998) R517
11. Sahai A., Khan M.S., Arya M., John J., Singh R., and Patel H.R.H. Expert Opin. Pharmacother. 7 (2006) 509
12. U.S. Food and Drug Administration, 2001. Guidance for Industry, Bioanalytical Method Validation, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, (http://www.fda.gov/cder/guidance/index.htm).
13. Hawes E.M. Drug Metab. Dispos. 26 (1998) 830